Effect of non-steroidal anti-inflammatory drugs on the histology of basal cell carcinomas

European Journal of Dermatology

Volumn 22, Issue 2, 2012, Pages 205-210

  Husein El Ahmed, Husein ^a   Aneiros Fernandez, Jose ^a   Gutierrezsalmeron, Maria Teresa ^a   Aneiros Cachaza, Jose ^a   Naranjo Sintes, Ramon ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Basal cell carcinoma; Non steroidal anti inflammatory drugs

Indexed keywords

ACEMETACIN; ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; DIFLUNISAL; ETODOLAC; FENOPROFEN; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; TENOXICAM;

AGED; ARTICLE; BASAL CELL CARCINOMA; CARCINOGENESIS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; HUMAN TISSUE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; POPULATION BASED CASE CONTROL STUDY; RISK ASSESSMENT;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOMA, BASAL CELL; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; SKIN NEOPLASMS;

EID: 84859746005     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1625     Document Type: Article

References (67)

1. Higashi Y, Kanekura T, Kanzaki T. Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression. Int J Cancer 2000; 86(5):667-671.
2. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276:18563-18569.
3. Abdelrahim M, Baker CH, Abbruzzese JL, et al. Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. Cancer Res 2007; 67:3286-3294.
4. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999; 59:991-994.
5. Ferrandina G, Legge F, Ranelletti FO, et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 2002; 95:801-807.
6. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001; 7:861-867.
7. Maitra A, Ashfaq R, Gunn CR, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 2002; 118:194-201.
8. Marrogi A, Pass HI, Khan M, Metheny-Barlow LJ, Harris CC, Gerwin BI. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res 2000; 60:3696-3700.
9. Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999; 46:407-412.
10. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000; 6:2424-2430.
11. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001; 61:4375-4381.
12. Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol 2007; 156(suppl 3):25-33.
13. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Reduction of UVinduced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999; 20(10):1939-1944.
14. Fischer SM, Lo H-H, Gordon GB, et al. Chemopreventative activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet lightinduced skin carcinogenesis. Mol Carcinog 1999; 25(4):231-240.
15. Reeve VE, Matheson MJ, Bosnic M, Boehm-Wilcox C. The protective effect of indomethacin on photocarcinogenesis in hairless mice. Cancer Lett 1995; 95(1-2):213-219.
16. Tang X, Kim AL, Kopelovich L, Bickers DR, Athar M. Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice. Photochem Photobiol 2008; 84(2):522-527.
17. Sorensen HT, Friis S, Nørgård B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 88(11):1687-1692.
18. Friis S, Sørensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003; 88(5):684-688.
19. Grau MV, Baron JA, Langholz B, et al. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer. Int J Cancer 2006; 119(3):682-686.
20. Butler GJ, Neale R, Green AC, Pandeya N, Whiteman DC. Nonsteroidal antiinflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005; 53(6):966-972.
21. Al-Saleem T. Nonsteroidal anti-inflammatory drugs in skin cancer: revisited. J Natl Cancer Inst 1993; 85(7):581-582.
22. Logan RF, Grainge MJ, Shepherd VC, Armitage NC, Muir KR; ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134(1): 29-38.
23. Baron JA, Sandler RS, Bresalier RS, et al.; APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131(6):1674-1682.
24. Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib antiaromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008; 111(1-2):13-17.
25. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004; 90(1):93-99.
26. Khuder SA, Herial NA, Mutgi AB, Federman DJ. Nonsteroidal anti-inflammatory drug use and lung cancer: a metaanalysis. Chest 2005; 127(3):748-754.
27. Elmets CA, Viner JL, Pentland AP, et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010 15;102(24):1835-44.
28. Arber N. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev 2008; 17(8):1852-7.
29. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004; 4:29-42.
30. Sinicrope FA. Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog 2006; 45:447-54.
31. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83(3):493-501.
32. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6(12): 4739-44.
33. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000; 19(1-2):19-27.
34. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000; 6(1): 135-8.
35. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93(5):705-16.
36. Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79(12): 1469-77.
37. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5(12):1418-23.
38. Buckman SY, Gresham A, Hale P et al. COX 2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19:723-9.
39. Kim KH, Park EJ, Seo Y et al. Immunohistochemical study of cyclooxygenase 2 and p53 expression in skin tumors. J Dermatol 2006; 33:319-25.
40. Dohadwala M, Luo J, Zhu L et al. Non small cell lung cancer cyclooxygenase 2 dependent invasion is mediated by CD44. J Biol Chem 2001; 276:20809-12.
41. Yu M, Zloty D, Cowan B, Shapiro J et al. Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J Invest Dermatol 2008;128(7):1797-805 [Epub 2008 Jan 17].
42. Bennett A, Del Tacca M. Proceedings: Prostaglandins in humancolonic carcinoma. Gut 1975; 16:409.
43. Jaffe BM. Prostaglandins and cancer: an update. Prostaglandins 1974; 6:453-61.
44. Kaporis HG, Guttman-Yassky E, Lowes MA, et al. Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J Invest Dermatol 2007; 127:2391-8.
45. Lee SY, Choi HK, Lee KJ, et al. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother 2009;32(1):22-8.
46. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003; 111:727-35.
47. Karmali RA. Review: prostaglandins and cancer. Prostaglandins Med 1980; 5(1):11-28.
48. Anasagasti-Angulo L, Garcia-Vega Y, Barcelona-Perez S, Lopez-Saura P, Bello-Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer 2009; 9: 262.
49. Hui JL, Kluger MS, Madge LA, Lian Z, Bothwell ALM, Pober JS. Interferon gamma augments CD95(APO-1/Fas) and procaspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis. Am J Path 2002; 161:1485-1495.
50. Sypniewski D, Bednarek I, Gaka S, Loch T, Machnik G. Influence of interferon-alpha and ribavirin on the transcription of interferongamma and IFN-gamma receptor genes in Jurkat cells. Acta Pol Pharm 2008; 65:345-351.
51. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferonalpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5:2726-2734.
52. Katayama A, Ogino T, Bandoh N, Nonaka S, Harabuchi Y. Expression of CXCR4 and Its Down-Regulation by IFN-α in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2005; 11:2937-2946.
53. Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 2007;67(18):8865-73.
54. Bertheim U, Hofer PA, Engstrom-Laurent A, et al. The stromal reaction in basal cell carcinomas. A prerequisite for tumour progression and treatment strategy. Br J Plast Surg 2004; 57:429-39.
55. Kaur P, Mulvaney M, Carlson JA. Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol 2006;28(4):293-307.
56. Irie T, Tsujii M, Tsuji S et al. Synergistic antitumor effects of celecoxib with 5 fluorouracil depend on IFN-gamma. Int J Cancer 2007;121(4):878-83.
57. Sharma S, Zhu L, Yang SC, et al. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol 2005;175(2):813-9.
58. Li J, Wang G, Chu Y, Rong R, Zhu T. The clinical application of COX-2 inhibitors may strengthen the sensitivity of renal cell carcinoma to immunotherapy. Med Hypotheses 2008;71(4):527-9.
59. Kundu N, Walser TC, Ma X, Fulton AM. Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 2005;54(10):981-7.
60. Vico P, Fourez T, Nemec E, Andry G, Deraemaecker R: Aggressive basal cell carcinoma of the head and neck areas. Euro J Surg Oncol 21(5): 490-497, 1995.
61. Sexton M, Jones DB, Maloney ME: Histologic pattern analysis of basal cell carcinoma. J Am Acad Dermatol 23: 1118-1126, 1990.
62. Leffell D, Headington JT, Wong DS, Swanson NA: Aggressivegrowth basal cell carcinoma in young adults. Arch Dermatol 127(11): 1663-1667, 1991.
63. Brown C, Perry AE: Incidence of perineural invasion in histologically aggressive types of basal cell carcinoma. Am J Dermatopath 22: 123-125, 2000.
64. Wrone D, Swetter SM, Egbert BM, Smoller BR, Khavari PA: Increased proportion of aggressive-growth basal cell carcinoma in the Veteran's Affairs population of Palo Alto, California. J Am Acad Dermatol 35: 907-910, 1996.
65. Slater DN, Mckee PH. Minimum dataset for histopathological reporting of common skin cancers. London: The Royal College of Pathologists; 2002.
66. Pérez-Suárez B, Guerra-Tapia A. Sociodemographic characteristics of spanish skin cancer patients. Actas Dermosifiliogr 2008;99(2):119-26.
67. IARC Working Group on the Evaluation of Cancer Preventive Agents. IARC handbooks for cancer prevention. Vol. 1: Non-steroidal anti-inflammatory drugs. International Agency for Research on Cancer, WHO: Lyon, France, 1997.